Albuterol improves alveolar-capillary membrane conductance in healthy humans

Natalie E. Taylor, Sarah E. Baker, Thomas P Olson, Sophie Lalande, Bruce David Johnson, Eric M. Snyder

Research output: Contribution to journalArticle

Abstract

Background: Beta-2 adrenergic receptors (β2ARs) are located throughout the body including airway and alveolar cells. The β2ARs regulate lung fluid clearance through a variety of mechanisms including ion transport on alveolar cells and relaxation of the pulmonary lymphatics. We examined the effect of an inhaled β2-agonist (albuterol) on alveolar-capillary membrane conductance (DM) and pulmonary capillary blood volume (VC) in healthy humans. Methods: We assessed the diffusing capacity of the lungs for carbon monoxide (DLCO) and nitric oxide (DLNO) at baseline, 30 minutes, and 60 minutes following nebulized albuterol (2.5 mg, diluted in 3 mL normal saline) in 45 healthy subjects. Seventeen subjects repeated these measures following nebulized normal saline (age = 27 ± 9 years, height = 165 ± 21 cm, weight = 68 ± 12 kg, BMI = 26 ± 9 kg/m2). Cardiac output (Q), heart rate, systemic vascular resistance (SVR), blood pressure, oxygen saturation, forced expiratory volume at one-second (FEV1), and forced expiratory flow at 50% of forced vital capacity (FEF50) were assessed at baseline, 30 minutes, and 60 minutes following the administration of albuterol or saline. Results: Albuterol resulted in a decrease in SVR, and an increase in Q, FEV1, and FEF50 compared to saline controls. Albuterol also resulted in a decrease in VC at 60 minutes post albuterol. Both albuterol and normal saline resulted in no change in DLCO or DM when assessed alone, but a significant increase was observed in DM when accounting for changes in VC. Conclusion: These data suggest that nebulized albuterol improves pulmonary function in healthy humans, while nebulization of both albuterol and saline results in an increase in DM/VC.

Original languageEnglish (US)
Pages (from-to)19-25
Number of pages7
JournalClinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
Volume10
DOIs
StatePublished - Oct 12 2016

Fingerprint

Albuterol
Membranes
Alveolar Epithelial Cells
Lung
Vascular Resistance
Adrenergic beta-2 Receptors
Lung Volume Measurements
Ion Transport
Vital Capacity
Forced Expiratory Volume
Carbon Monoxide
Blood Volume
Cardiac Output
Adrenergic Receptors
Healthy Volunteers
Nitric Oxide
Heart Rate
Oxygen
Blood Pressure
Weights and Measures

Keywords

  • CFTR
  • Lung diffusion
  • Lung fluid
  • Sodium channels

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Albuterol improves alveolar-capillary membrane conductance in healthy humans. / Taylor, Natalie E.; Baker, Sarah E.; Olson, Thomas P; Lalande, Sophie; Johnson, Bruce David; Snyder, Eric M.

In: Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, Vol. 10, 12.10.2016, p. 19-25.

Research output: Contribution to journalArticle

@article{47bf388896084d6e89006f547a7f0e45,
title = "Albuterol improves alveolar-capillary membrane conductance in healthy humans",
abstract = "Background: Beta-2 adrenergic receptors (β2ARs) are located throughout the body including airway and alveolar cells. The β2ARs regulate lung fluid clearance through a variety of mechanisms including ion transport on alveolar cells and relaxation of the pulmonary lymphatics. We examined the effect of an inhaled β2-agonist (albuterol) on alveolar-capillary membrane conductance (DM) and pulmonary capillary blood volume (VC) in healthy humans. Methods: We assessed the diffusing capacity of the lungs for carbon monoxide (DLCO) and nitric oxide (DLNO) at baseline, 30 minutes, and 60 minutes following nebulized albuterol (2.5 mg, diluted in 3 mL normal saline) in 45 healthy subjects. Seventeen subjects repeated these measures following nebulized normal saline (age = 27 ± 9 years, height = 165 ± 21 cm, weight = 68 ± 12 kg, BMI = 26 ± 9 kg/m2). Cardiac output (Q), heart rate, systemic vascular resistance (SVR), blood pressure, oxygen saturation, forced expiratory volume at one-second (FEV1), and forced expiratory flow at 50{\%} of forced vital capacity (FEF50) were assessed at baseline, 30 minutes, and 60 minutes following the administration of albuterol or saline. Results: Albuterol resulted in a decrease in SVR, and an increase in Q, FEV1, and FEF50 compared to saline controls. Albuterol also resulted in a decrease in VC at 60 minutes post albuterol. Both albuterol and normal saline resulted in no change in DLCO or DM when assessed alone, but a significant increase was observed in DM when accounting for changes in VC. Conclusion: These data suggest that nebulized albuterol improves pulmonary function in healthy humans, while nebulization of both albuterol and saline results in an increase in DM/VC.",
keywords = "CFTR, Lung diffusion, Lung fluid, Sodium channels",
author = "Taylor, {Natalie E.} and Baker, {Sarah E.} and Olson, {Thomas P} and Sophie Lalande and Johnson, {Bruce David} and Snyder, {Eric M.}",
year = "2016",
month = "10",
day = "12",
doi = "10.4137/CCRPM.S30251",
language = "English (US)",
volume = "10",
pages = "19--25",
journal = "Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine",
issn = "1179-5484",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Albuterol improves alveolar-capillary membrane conductance in healthy humans

AU - Taylor, Natalie E.

AU - Baker, Sarah E.

AU - Olson, Thomas P

AU - Lalande, Sophie

AU - Johnson, Bruce David

AU - Snyder, Eric M.

PY - 2016/10/12

Y1 - 2016/10/12

N2 - Background: Beta-2 adrenergic receptors (β2ARs) are located throughout the body including airway and alveolar cells. The β2ARs regulate lung fluid clearance through a variety of mechanisms including ion transport on alveolar cells and relaxation of the pulmonary lymphatics. We examined the effect of an inhaled β2-agonist (albuterol) on alveolar-capillary membrane conductance (DM) and pulmonary capillary blood volume (VC) in healthy humans. Methods: We assessed the diffusing capacity of the lungs for carbon monoxide (DLCO) and nitric oxide (DLNO) at baseline, 30 minutes, and 60 minutes following nebulized albuterol (2.5 mg, diluted in 3 mL normal saline) in 45 healthy subjects. Seventeen subjects repeated these measures following nebulized normal saline (age = 27 ± 9 years, height = 165 ± 21 cm, weight = 68 ± 12 kg, BMI = 26 ± 9 kg/m2). Cardiac output (Q), heart rate, systemic vascular resistance (SVR), blood pressure, oxygen saturation, forced expiratory volume at one-second (FEV1), and forced expiratory flow at 50% of forced vital capacity (FEF50) were assessed at baseline, 30 minutes, and 60 minutes following the administration of albuterol or saline. Results: Albuterol resulted in a decrease in SVR, and an increase in Q, FEV1, and FEF50 compared to saline controls. Albuterol also resulted in a decrease in VC at 60 minutes post albuterol. Both albuterol and normal saline resulted in no change in DLCO or DM when assessed alone, but a significant increase was observed in DM when accounting for changes in VC. Conclusion: These data suggest that nebulized albuterol improves pulmonary function in healthy humans, while nebulization of both albuterol and saline results in an increase in DM/VC.

AB - Background: Beta-2 adrenergic receptors (β2ARs) are located throughout the body including airway and alveolar cells. The β2ARs regulate lung fluid clearance through a variety of mechanisms including ion transport on alveolar cells and relaxation of the pulmonary lymphatics. We examined the effect of an inhaled β2-agonist (albuterol) on alveolar-capillary membrane conductance (DM) and pulmonary capillary blood volume (VC) in healthy humans. Methods: We assessed the diffusing capacity of the lungs for carbon monoxide (DLCO) and nitric oxide (DLNO) at baseline, 30 minutes, and 60 minutes following nebulized albuterol (2.5 mg, diluted in 3 mL normal saline) in 45 healthy subjects. Seventeen subjects repeated these measures following nebulized normal saline (age = 27 ± 9 years, height = 165 ± 21 cm, weight = 68 ± 12 kg, BMI = 26 ± 9 kg/m2). Cardiac output (Q), heart rate, systemic vascular resistance (SVR), blood pressure, oxygen saturation, forced expiratory volume at one-second (FEV1), and forced expiratory flow at 50% of forced vital capacity (FEF50) were assessed at baseline, 30 minutes, and 60 minutes following the administration of albuterol or saline. Results: Albuterol resulted in a decrease in SVR, and an increase in Q, FEV1, and FEF50 compared to saline controls. Albuterol also resulted in a decrease in VC at 60 minutes post albuterol. Both albuterol and normal saline resulted in no change in DLCO or DM when assessed alone, but a significant increase was observed in DM when accounting for changes in VC. Conclusion: These data suggest that nebulized albuterol improves pulmonary function in healthy humans, while nebulization of both albuterol and saline results in an increase in DM/VC.

KW - CFTR

KW - Lung diffusion

KW - Lung fluid

KW - Sodium channels

UR - http://www.scopus.com/inward/record.url?scp=85012149778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012149778&partnerID=8YFLogxK

U2 - 10.4137/CCRPM.S30251

DO - 10.4137/CCRPM.S30251

M3 - Article

AN - SCOPUS:85012149778

VL - 10

SP - 19

EP - 25

JO - Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

JF - Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

SN - 1179-5484

ER -